The cost to treat rare disease can be extraordinary.
The cost to treat rare disease can be extraordinary. Several orphan drugs which were just approved this year, ranged from $150,000 at the low-end, to as much as $300,000 or more annually. The high costs of these drugs raise questions as to the sustainability of such treatments, and whether or not the healthcare system might absorb these costs, or how payers will make coverage decisions.
Although orphan drugs account for a small percentage of prescription drug costs, a recent survey finds that three quarters of all pharmacy directors are moderately to extremely concerned about the impact these drugs have on overall spending, and most of those same directors are seeking a way to mitigate projected costs. The survey, which was conducted by the healthcare-focused investment bank Leerink Swann, analyzed 34 pharmacy directors who work at insurers or pharmacy benefit managers responsible for $46 billion in medical spending and who cover 123 million consumers.
Additional survey findings showed that directors could not accurately determine the number of patients using orphan drugs, that 40% did not use metrics to measure impact usage has on spending, and only 30% anticipated policy changes by 2015 towards these medications. Joseph Schwartz, an analyst at Leerink Swann, also said that the pharmacy directors estimated 6.4% of pharmacy-benefit spending and 4.1% of medical benefit spending was on orphan drugs. Conversely, the Centers for Medicaid & Medicare Services reports that orphan drugs account for less than half a percent of US healthcare spending.
“We continue to believe that a distinction between sticker shock and budget impact deserves to be drawn,” Mr Schwartz stated.
The survey suggests that by 2015, almost all of the polled directors expect orphan drugs to be considered a medical benefit, to make greater use of prior authorization, and to make better use of formularies and preferred drug lists. By 2019, the pharmacy directors predict even larger changes in pricing and access of orphan drugs.
Mr Schwartz says that patient advocacy groups remain vigilant in lobbying for continued research and coverage of orphan drugs. “Their influence should not be underestimated,” he wrote. “We believe payers realize how carefully they must tread in this area, so most changes to orphan drug coverage (and) access are likely to be evolutionary, rather than revolutionary, in our view.”
As the future of medical care calls for more personalized medicine delivery, the treatment of rare disease remains of special interest. However, the surveyed directors felt that managing costs for drugs used to treat cancer, chronic disease, or other conditions like diabetes and multiple sclerosis were more important than orphan drugs.
“It is estimated that over 7000 rare diseases have been identified today, affecting over 25 million Americans. Unfortunately, while rare diseases are often chronically debilitating, life limiting—and in some cases life threatening—they’re still frequently undermanaged and underdiagnosed,” Peter Saldo, MD, professor of medicine and anesthesiology at Columbia University said in a recent AJMCtv Peer Exchange. “Policy and regulatory changes have helped to pave a thriving foundation for further clinical research and development leading to the development of novel drug agents that utilize genetic and cellular components.”
Continued policy and regulatory changes may be necessary in order to maintain the sustainability of producing orphan drugs for those with rare disease.
Around the Web
Sticker Shock: Will Orphan Drug Reimbursement Remain Stable? [Forbes]
Recognizing Rare Diseases in the United States [AJMC]
Recognizing Rare Diseases in the United States
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More